Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Baseline characteristics of exercise and non-exercise groups

From: Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

  EXE (n = 16) NoEXE (n = 19) P
Age (yr) 68.6 ± 8.4 66.3 ± 9.0 0.45
Height (cm) 170.8 ± 8.5 171.6 ± 7.8 0.76
Weight (kg) 85.0 ± 17.8 77.0 ± 12.1 0.13
BMI (kg·m−2) 28.5 ± 4.7 26.1 ± 4.0 0.12
ADT duration (mo) 14.6 ± 15.4 12.7 ± 11.6 0.67
Gleason score 7.4 ± 0.9 7.6 ± 0.9 0.50
Time since diagnosis (yr) 4.7 ± 5.1 4.7 ± 4.9 0.99
Testosterone (ng·dl−1) 25.0 ± 7.3 6.3 ± 37.4 0.26
PSA (ng·ml− 1) 2.1 ± 4.4 0.8 ± 2.4 0.28
Number of comorbiditiesa 2.6 ± 1.9 1.7 ± 1.4 0.13
Number of medications 3.0 ± 2.5 4.1 ± 3.3 0.28
Anti-androgen, n (%) 8 (50%) 12 (63.1%) 0.43
Metastatic disease, n (%) 10 (62.5%) 9 (47.3%) 0.50
Metastases type, n (%)    0.36
 Nodal metastases 2 (12.5%) 2 (10.5%)  
 Bone metastases 6 (37.5%) 7 (36.8%)  
 Other metastases sitesb 2 (12.5%) 0 (0%)  
Ethnicity, n (%)    0.88
 White 8 (50.0%) 11 (57.9%)  
 African American 2 (12.5%) 1 (10.5%)  
 Asian/Pacific Islander 4 (25.0%) 5 (26.3%)  
 Hispanic 2 (12.5%) 2 (10.5%)  
Previous radiation, n (%) 8 (53.3%) 10 (52.6%) 0.97
Previous surgery, n (%) 12 (75.0%) 12 (63.1%) 0.45
Previous chemotherapy, n (%) 2 (12.5%) 2 (10.5%) 0.86
Caloric intake (kcal·day−1) 1903.0 ± 629.4 1688.1 ± 376.3 0.26
Protein intake (g·kg− 1·day− 1) 1.0 ± 0.4 1.1 ± 0.5 0.59
Total physical activity (min·wk.− 1)c 654.8 ± 789.5 999.1 ± 910.8 0.31
 Moderate activity (min·wk.− 1) 221.4 ±  210.3 397.3 ±  429.2 0.36
 Vigorous activity (min·wk.− 1) 144.6 ±  323.8 129.2 ±  151.5 0.86
  1. Data presented as mean ± standard deviation or number of participants (% of participants)
  2. P, significance level; EXE, exercise groups (TRAINPRO and TRAIN); NoEXE, non-exercise groups (PRO and STRETCH); ADT, androgen deprivation therapy; PSA, prostate-specific antigen
  3. aCardiovascular disease, hypertension, diabetes, osteoporosis and dyslipidemia
  4. bKidney, liver
  5. cIncludes light walking, moderate and vigorous activity